CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 2,004 enrolled
Drug / intervention
ChimeriVax-JE, Japanese Encephalitis vaccine +1 morebiological
Likely dose
ChimeriVax-JE, Japanese Encephalitis vaccine 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00314132
NCT00314132Phase 3Completed
CompareCT.gov

Randomised, Double Blind, Multicentre, Placebo Controlled Phase III Study of the Safety and Tolerability Following Administration of Live Attenuated JE Vaccine (ChimeriVax™-JE)

Sanofi·interventional·Posted Apr 13, 2006·Updated Dec 6, 2012

In Brief

A Phase 3 clinical trial evaluating ChimeriVax-JE, Japanese Encephalitis vaccine and 0.9% Saline for Encephalitis and Japanese Encephalitis. Completed, enrolled 2,004 participants across 22 sites in 2 countries.

Detailed Summary

The purpose of this study is to assess whether ChimeriVax™ JE vaccine (a new vaccine to be used for vaccination against Japanese encephalitis) is safe and well tolerated when compared to placebo (dummy) vaccination.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEncephalitis, Japanese Encephalitis
CountriesAustralia, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 13, 2006
Enrollment StartOct 1, 2005
Primary CompletionNov 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 20.2 years ago

Interventions

ChimeriVax-JE, Japanese Encephalitis vaccinebiological

0.5 mL, Subcutaneous

0.9% Salinebiological

0.5 mL, Subcutaneous